Landos Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Greg Oakes

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage	52.1%
CEO tenure	1.9yrs
CEO ownership	n/a
Management average tenure	1.7yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Jun 14

Landos Biopharma (LABP) Investor Presentation - Slideshow

Jun 08

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

May 04

CEO Compensation Analysis

How has Greg Oakes's remuneration changed compared to Landos Biopharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$25m
Dec 31 2023	US$1m	US$613k	-US$22m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$2m	US$321k	-US$39m

Compensation vs Market: Greg's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD661.15K).

Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.

CEO

Greg Oakes (54 yo)

1.9yrs

Tenure

US$1,175,302

Compensation

Mr. Gregory Oakes, also known as Greg, is President, Chief Executive Officer & Director of Landos Biopharma, Inc. since June 2022. He serves as President of North America, Relypsa, Inc. He served as Presid...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gregory Oakes	President	1.9yrs	US$1.18m	no data
Fabio Cataldi	Executive VP & Chief Medical Officer	1.7yrs	US$885.15k	0% $ 0
Jennifer Creel	Interim Chief Financial Officer	less than a year	no data	no data
Rebecca Mosig	Vice President of Corporate Development	1.3yrs	no data	no data
Josep Bassaganya-Riera	Advisor	2.5yrs	US$2.07m	no data

1.7yrs

Average Tenure

53yo

Average Age

Experienced Management: LABP's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Gregory Oakes	President	1.9yrs	US$1.18m	no data
Timothy Mayleben	Director	3yrs	US$56.79k	0% $ 0
Frederick Callori	Independent Director	2.8yrs	US$73.26k	0% $ 0
Christopher Garabedian	Independent Chairman	6.7yrs	US$89.29k	0% $ 0
Roger Adsett	Independent Director	2.2yrs	US$59.29k	0% $ 0
Alka Batycky	Independent Director	less than a year	US$40.34k	0% $ 0
Tiago Girao	Independent Director	3.1yrs	US$76.79k	0% $ 0

2.8yrs

Average Tenure

54yo

Average Age

Experienced Board: LABP's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Landos Biopharma Management

Management criteria checks 1/4

Key information

Recent management updates

Landos Biopharma, Inc., Annual General Meeting, May 23, 2024

Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023

Landos Biopharma, Inc. Appoints Alka Batycky to its Board of Directors and Audit Committee

High number of new and inexperienced directors

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

High number of new and inexperienced directors

Recent updates

Landos Biopharma, Inc., Annual General Meeting, May 23, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

New minor risk - Share price stability

Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting

Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023

Price target decreased by 52% to US$5.00

Landos Biopharma, Inc. Appoints Alka Batycky to its Board of Directors and Audit Committee

Price target decreased by 48% to US$0.55

Price target decreased by 48% to US$0.55

Price target increased by 82% to US$2.00

Landos Biopharma, Inc. announced that it expects to receive $16.690909 million in funding from Perceptive Advisors LLC

Nasdaq Grants Landos Biopharma an Additional 180-Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Price Requirement

Price target decreased to US$1.10

High number of new and inexperienced directors

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer

Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Landos Biopharma, Inc. Reports Positive Top-Line Results from NX-13 Phase 1B Trial

High number of new and inexperienced directors

High number of new and inexperienced directors

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell 2000 Growth Index

Landos Biopharma, Inc. Names Gregory Oakes as Chief Executive Officer

Landos Biopharma Receives Non-Compliance Letter from Nasdaq

Landos Biopharma, Inc. Announces Executive Changes

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Price target decreased to US$18.82

High number of new and inexperienced directors

Roderick Wong Not Stand for Re-Election as Director of the Landos Biopharma, Inc

Price target decreased to US$18.82

Dr. Raquel Hontecillas, the Chief Scientific Officer of Landos Biopharma, Inc. Is No Longer with the Company

High number of new and inexperienced directors

Insider notifies of intention to sell stock

Insider recently sold US$456k worth of stock

Insider recently sold US$645k worth of stock

Insider recently sold US$364k worth of stock

Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Independent Director Konstantin Poukalov has left the company

Landos Biopharma’S Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation At the United European Gastroenterology Week 2021

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell Microcap Value Index

Landos Biopharma, Inc. Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis Patients

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Landos Biopharma (LABP) Investor Presentation - Slideshow

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

Landos Biopharma Announces Positive Results from A Phase 1 Study of NX-13 in Healthy Volunteers

Landos Biopharma, Inc. has completed an IPO in the amount of $100 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age